Skip to main content
profile image
Selected Works of Pearl Kwong, MD, PhD, FAAD
Article
COVE-1: A Phase 2, Open-Label Study to Evaluate Efficacy and Safety and the Optimal Regimen of VP-102, a Proprietary Drug-Device Product Containing Topical Cantharidin (0.7% w/v) Under Occlusion for the Treatment of Common Warts.
Dermatologic Therapy (2021)
  • Scott Guenthner, The Indiana Clinical Trials Center, Plainfield, IN, USA.
  • Wendy McFalda, Clarkston Skin Research, Clarkston, MI, USA.
  • Pearl Kwong, Solutions Through Advanced Research, Jacksonville, FL, USA.
  • Kimberly Eads, The Indiana Clinical Trials Center, Plainfield, IN, USA.
  • Morgan McCafferty, Durham University
  • Jayson Rieger, PBM Capital Group, Charlottesville, VA, USA.
  • David K Glover, PBM Capital Group, Charlottesville, VA, USA.
  • Cynthia Willson, Verrica Pharmaceuticals Inc, West Chester, PA, USA.
  • Patrick Burnett, Verrica Pharmaceuticals Inc, West Chester, PA, USA.
  • Melissa Olivadoti, Verrica Pharmaceuticals Inc, West Chester, USA
Link
Disciplines
Publication Date
July 21, 2021
DOI
10.1007/S13555-021-00576-Y
Citation Information
Scott Guenthner, Wendy McFalda, Pearl Kwong, Kimberly Eads, et al.. "COVE-1: A Phase 2, Open-Label Study to Evaluate Efficacy and Safety and the Optimal Regimen of VP-102, a Proprietary Drug-Device Product Containing Topical Cantharidin (0.7% w/v) Under Occlusion for the Treatment of Common Warts." Dermatologic Therapy (2021) p. 1 - 12
Available at: http://works.bepress.com/pearl-kwong/23/